0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Plasmapheresis Does Not Increase the Risk for Infection in Immunosuppressed Patients with Severe Lupus Nephritis

Marc A. Pohl, MD; Shu-Ping Lan, MA, MPH; Tomas Berl, MD, Lupus Nephritis Collaborative Study Group*
[+] Article and Author Information

Grant Support: By USPHS grant number R01-DK-27770.

Requests for Reprints: Marc A. Pohl, MD, Department of Hypertension and Nephrology, The Cleveland Clinic Foundation, One Clinic Center, 9500 Euclid Avenue, Cleveland, OH 44195-5042.

Current Author Addresses: Dr. Pohl: Department of Hypertension and Nephrology, The Cleveland Clinic Foundation, One Clinic Center, 9500 Euclid Avenue, Cleveland, OH 44195-5042.

Dr. Berl: C281, University of Colorado School of Medicine, 4200 East 9th Avenue, Denver, CO 80262.

Ms. Lan: The Biostatistics Center, 6110 Executive Boulevard, #750, Rockville, MD 20852.


©1991 American College of PhysiciansAmerican College of Physicians


Ann Intern Med. 1991;114(11):924-929. doi:10.7326/0003-4819-114-11-924
Text Size: A A A

Objective: To determine whether plasmapheresis increases the risk for infection in immunosuppressed patients.

Design: Randomized, controlled trial.

Setting: Multicenter.

Patients: Eighty-six patients enrolled in a trial of plasmapheresis for severe diffuse proliferative lupus nephritis.

Interventions: Forty-six of the patients received high-dose steroid therapy plus cyclophosphamide therapy for 8 weeks. Thereafter, cyclophosphamide therapy was discontinued, and steroid therapy was tapered (standard treatment group). Forty patients received identical treatment and had 12 plasmapheresis procedures during the first 4 weeks of the treatment.

Measurements: Patients were examined for the development of infection.

Main Results: No statistical difference in age, sex, race, serum creatinine level, proteinuria, or complement levels was found between the two groups. Over a follow-up period of 5376 patientweeks, 74% of patients in the standard treatment group had 62 infections, yielding an aggregate infection rate of 1.15 infections per 100 weeks (median individual infection rate, 1.08; 25th and 75th percentiles, 0.0 and 2.44). This rate was comparable to that seen in the plasmapheresis-treated patients who were followed for 4187 patient-weeks: 68% had 51 infections, for an aggregate infection rate of 1.22 infections per 100 weeks (median individual infection rate, 0.94; 25th and 75th percentiles, 0.0 and 2.32). The infection rate was also comparable in the initial acute phase of the study, despite the fact that patients who received plasmapheresis then had significantly lower immunoglobulin (IgG) levels (P < 0.001). Neither the site (superficial compared with systemic) nor the nature (conventional compared with unconventional) of infection differed statistically between the two groups. Of 14 patient deaths, 7 were from infection (4 in the control group and 3 in the plasmapheresis group).

Conclusion: Plasmapheresis did not increase the risk for infection in immunosuppressed patients with severe lupus nephritis.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)